All lobbying filings

THE MCMANUS GROUP

Lobbying for GENENTECH

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.

Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.